Key terms
About BMY
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BMY news
Yesterday
5:20pm ET
Bristol Myers Squibb (NYSE:BMY) Slips after Disappointing Drug Trial
Mar 25
11:46am ET
Bristol Myers Squibb call volume above normal and directionally bullish
Mar 20
4:52pm ET
Bristol Myers’ Abecma approved in the EU for multiple myeloma
Mar 20
7:05am ET
Bristol Myers says Phase 3 CheckMate -9DW trial met primary endpoint
Mar 20
7:01am ET
Bristol Myers announces the Phase 3 CheckMate -9DW trial
Mar 19
1:32pm ET
This radiopharma name seen as ‘poised for takeout’ following Fusion deal
Mar 19
12:55pm ET
Actinium Pharmaceuticals price target raised to $30 from $20 at Maxim
Mar 19
1:37am ET
Hold Rating on Bristol-Myers Squibb Amidst NSCLC Trial Uncertainties and Pending KarXT Results
Mar 18
5:52pm ET
Gerald Storch Exits, Bristol-Myers Squibb Board Shrinks
Mar 18
9:19am ET
Arcellx price target raised to $81 from $72 at Needham
Mar 18
9:07am ET
Bristol Myers completes acquisition of Karuna Therapeutics
Mar 18
8:15am ET
Perspective Therapeutics announces collaboration agreement with Bristol Myers
Mar 18
5:15am ET
Hold Rating on Bristol-Myers Squibb Amid Mixed Clinical Outcomes and Market Competition
Mar 15
6:30pm ET
Bristol Myers, 2seventy Bio: FDA’s ODAC votes in favor of Abecma
Mar 15
12:03pm ET
JPMorgan biotech/pharma analysts hold an analyst/industry conference call
Mar 15
5:11am ET
Bristol Myers announces FDA grants accelerated approval of Breyanzi
Mar 14
7:16am ET
Hold Rating on Bristol-Myers Squibb Amid Concerns Over Abecma’s Efficacy and Safety
Mar 12
6:59pm ET
Bristol Myers’ repotrectinib receives FDA orphan designation
Mar 12
8:37am ET
Truist Financial Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)
Mar 11
2:48pm ET
Bristol-Myers Squibb (NYSE:BMY) Shrugs off Analyst Cut
Mar 11
12:43pm ET
Bristol Myers downgraded to Hold from Buy at Societe Generale
Mar 07
2:26pm ET
Bristol Myers reports FDA approves Opdivo for first-line metastatic UC treatment
Mar 05
11:39am ET
Healthcare Stocks Mostly In Retreat After New Task Force Announced
Mar 05
7:32am ET
2seventy Bio: Abecma generated $56M U.S. commercial revenue in Q4
Feb 29
7:02am ET
Bristol Myers’ ozanimod shows efficacy and safety in multiple sclerosis trial
Feb 27
6:02am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), Krystal Biotech (KRYS) and Bristol-Myers Squibb (BMY)
Feb 27
5:58am ET
Bristol-Myers Squibb: Balancing Growth Prospects Against Market Challenges and Uncertainties
Feb 26
11:45am ET
Truist biotech analysts hold an analyst/industry conference call
Feb 26
9:17am ET
Bristol Myers completes acquisition of RayzeBio
Feb 26
4:55am ET
Truist biotech analysts hold an analyst/industry conference call
Feb 23
7:49am ET
C4 Therapeutics price target raised to $13 from $12 at Stifel
BMY Financials
Key terms
Ad Feedback
BMY Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BMY Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range